Can a natural compound boost chemotherapy against endometrial cancer?

NCT ID NCT07738315

Not yet recruiting Disease control Sponsor: Women's Hospital School Of Medicine Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial is testing whether adding elemene liposomes—a compound derived from a traditional Chinese medicinal plant—to standard chemotherapy (carboplatin and paclitaxel) can help people with advanced or recurrent endometrial cancer. Participants will receive either the combination or chemotherapy alone. The main goal is to see if the combination delays cancer progression for at least two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Elemene liposomes (intravenous and oral) combined with carboplatin-paclitaxel chemotherapy
What this could lead to: If adding elemene liposomes to standard chemotherapy delays cancer progression, it could offer a new treatment option for advanced or recurrent endometrial cancer.
What could go wrong: This is a phase 2 trial, so results are preliminary. The combination may not improve outcomes and could increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial carcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CARCINOMA

Contacts and locations

Locations

Women's hospital School of Medicine Zhejiang University

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.